---
MDMA

MDMA

MDMA, an investigational medicinal product (IMP), is an entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine (NE), and dopamine.

MDMA has demonstrated potential efficacy in clinical trials to treat AUD and Post Traumatic Stress Disorder (PTSD), conditions that have trauma as a significant causative factor.

MDMA could also potentially be effective in treating other addictions and mental health conditions which also have trauma as a causative factor. 

While MDMA shows excellent promise in trials there are issues that challenge the successful development of MDMA as a marketed drug:

Excessive Treatment Duration: Treatment sessions last between 6 to 8 hours.

Variable Pharmacokinetics: Gastrointestinal absorption and first-pass metabolism negatively effects bioavailability.

MDMA/Zydis Program

Awakn is addressing these challenges by developing a market-ready proprietary formulation and optimized delivery route for MDMA.

Status: Awakn has executed an exclusive development agreement with Catalent, a global leader in drug formulation. The agreement focuses on developing and testing a market-ready proprietary formulation and optimized delivery route for MDMA using Catalent’s proprietary Zydis platform orally disintegrating tablet (ODT) technology. 

Next steps: Potential excusive global licensing agreement with Catalent for MDMA on their Zydis platform ODT technology. Followed by single species toxicology and the healthy volunteers phase I trial.

Zydis Technology

• Zydis® ODT fast-dissolve formulationis a unique, patent protected freeze-dried oral solid dosageform that disperses almost instantly, typically less than 3 seconds in the mouth – no water required
• Enhances pharmacokinetics through pre-gastric absorption, to improve PK and patient compliance
• Faster onset of effects
• Possibility to shorten therapy sessions, reducing cost, improving experience and outcomes
• Fully patented
  

Proposed Timeline and Milestones – Mdma/Zydis

Sign Up for Newsletter

MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom

© 2023 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy